Your browser doesn't support javascript.
loading
Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
Schmidt, Christin; Schubert, Nil A; Brabetz, Sebastian; Mack, Norman; Schwalm, Benjamin; Chan, Jennifer A; Selt, Florian; Herold-Mende, Christel; Witt, Olaf; Milde, Till; Pfister, Stefan M; Korshunov, Andrey; Kool, Marcel.
Afiliación
  • Schmidt C; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Schubert NA; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Brabetz S; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Mack N; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Schwalm B; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Chan JA; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Selt F; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Herold-Mende C; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Witt O; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Milde T; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Pfister SM; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Korshunov A; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
  • Kool M; Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany; Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute an
Neuro Oncol ; 19(12): 1607-1617, 2017 Nov 29.
Article en En | MEDLINE | ID: mdl-28482026
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pteridinas / Neoplasias Encefálicas / Tumores Neuroectodérmicos Primitivos / Neoplasias de Células Germinales y Embrionarias / Topotecan / Dactinomicina Tipo de estudio: Guideline Límite: Animals / Child, preschool / Female / Humans Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pteridinas / Neoplasias Encefálicas / Tumores Neuroectodérmicos Primitivos / Neoplasias de Células Germinales y Embrionarias / Topotecan / Dactinomicina Tipo de estudio: Guideline Límite: Animals / Child, preschool / Female / Humans Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido